Risk of skin neoplasm related to the use of immunomodulatory abatacept (2016)
Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Sciences and Technology Meeting of the Faculty of Pharmaceutical Sciences, University of São Paulo. Unidade: FCF
Subjects: NEOPLASIAS, ADJUVANTES IMUNOLÓGICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEDRO, Letícia Sybilla Borges e RIBEIRO, Adalton Guimarães e KANO, Eunice Kazue. Risk of skin neoplasm related to the use of immunomodulatory abatacept. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 11 nov. 2024. , 2016APA
Pedro, L. S. B., Ribeiro, A. G., & Kano, E. K. (2016). Risk of skin neoplasm related to the use of immunomodulatory abatacept. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Pedro LSB, Ribeiro AG, Kano EK. Risk of skin neoplasm related to the use of immunomodulatory abatacept. Brazilian Journal of Pharmaceutical Sciences. 2016 ; 52 47 res. FCF090.[citado 2024 nov. 11 ]Vancouver
Pedro LSB, Ribeiro AG, Kano EK. Risk of skin neoplasm related to the use of immunomodulatory abatacept. Brazilian Journal of Pharmaceutical Sciences. 2016 ; 52 47 res. FCF090.[citado 2024 nov. 11 ]
